Brief: Lantern Pharma And Ttc Oncology Establish Ai Collaboration To Expand The Clinical Development Of Drug Candidate Ttc-352
27/02/2023 13:57
Feb 27 (Reuters) - Lantern Pharma Inc LTRN.O :
* LANTERN PHARMA AND TTC ONCOLOGY ESTABLISH AI COLLABORATION
TO
EXPAND THE CLINICAL DEVELOPMENT OF DRUG CANDIDATE TTC-352
* LANTERN PHARMA IS RECEIVING EXCLUSIVE RIGHT TO LICENSE
TTC-352,
INCLUDING ANY COLLABORATION IP DURING AN EXCLUSIVE OPTION PERIOD
Source text for Eikon: ID:nBw9G63VKa
Further company coverage: LTRN.O
((Reuters.Briefs@thomsonreuters.com))
Recent news on Lantern Pharma
See all newsBrief: Lantern Pharma Receives Taiwan Approvals To Open Next Stage Of Phase 2 Harmonic Trial Of Lp-300 In Never-Smoker, Egfr-Mutant Nsclc
Brief: Lantern Pharma Reports Second Quarter 2026 Financial Results And Provides Business Update
Lantern Pharma Inc reports results for the quarter ended June 30 - Earnings Summary
Lantern Pharma Q2 operating loss widens on warrant expenses tied to higher stock price
Lantern Pharma Inc expected to post a loss of 38 cents a share - Earnings Preview